BCYC News and Press, Bicycle Therapeutics plc From 06/23/20

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the appointment of Sir Keith Peters FRS as Chairman of the Company’s Scie...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that new translational data for BT5528 and preclinical data for tumor-targeted...

In 2018, the founder of Bicycle Therapeutics   (NASDAQ: BCYC) , Sir Gregory Winter, was awarded the Nobel Prize in chemistry for his work in developing phage display (use of viruses that infect bacteria to connect proteins) to produce antibodies and peptides (small chains of amino acids) f...

The following slide deck was published by Bicycle Therapeutics plc in conjunction with this Read more ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in fireside chats at the following virtual inve...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that new translational research for second-generation Bicycle® Toxin Conjug...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT5528 wi...

- BT5528 optimized to have distinct physiochemical and in vivo properties thought to enable more favorable preclinical safety, efficacy profiles than those of an antibody drug conjugate Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differenti...

Bicycle Therapeutics (NASDAQ: BCYC ): Q1 GAAP EPS of -$0.63 misses by $0.55 . More news on: Bicycle Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...

- Significant recent progress achieved across pipeline of innovative Bicycle ® - based therapies for oncology and beyond - Dosing underway in Phase I dose escalation of BT5528 in combination with nivolumab - Continued to strengthen corporate leadership with appointment of Ge...